LiverLearning®: Transplant Surgery Workshop: Changing Donors, Recipients and Organ Use

This program will look at current political issues related to organ allocation supported by data and an open debate, as well as changes in listing criteria. In addition, speakers will address best practices for the use of marginal livers and innovative treatment options to use such organs.Peter L. Abt Karen E. Doucette Dennis Irwin David S. Goldberg David J. Reich George E. Loss Karim Halazun Timothy L. Pruett

LiverLearning®: Portal Hypertension SIG: Critical Review of Invasive Interventions in Patients with Portal Hypertension

Join international portal hypertension experts for a critical review of several invasive interventions performed in patients with the disease. This session will look at potential situations that may interfere with the accuracy and reproducibility of hepatic venous pressure gradient and portal pressure gradient measurements in the course of TIPS. It will also discuss recommendations for standardizing the procedure.

LiverLearning®: Liver Cell Biology in Hepatic Diseases SIG: DAMPs and New Receptor Signaling in Liver Disease

Gain a solid background on the mechanisms that activate and potentiate hepatic injury, inflammation and fibrosis through an in-depth presentation of the different yet related basic molecular mechanisms that underlie various types of hepatic damage.Melanie J. Scott Xiaoxia Li Nissiam Hay Yingzi Yang

LiverLearning®: Hepatitis B SIG: Getting to HBV Cure: The Path Forward

There is a critical need for curative therapy for hepatitis b (HBV). This program will systematically review the various approaches to achieving this goal. Attendees will gain a greater appreciation for the challenges in developing new HBV therapies and discover where new therapies will fit into the future treatment landscape for this disease.Jordan J. Feld Jordan J. Feld, MD, MPH, FAASLD attended medical school at the University of Toronto and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr.

LiverLearning®: NAFLD SIG: Non-Invasive Diagnosis of NASH: We're getting There

Review the rapidly evolving landscape of non-invasive diagnostic tools for the diagnosis and staging of NAFLD. Non-invasive Diagnosis of NASH will look at the current role of — and available alternatives to —liver biopsy in the assessment of NASH and discuss the controversial issue of utilizing liver biopsy as the “gold-standard” endpoint in clinical trials.

LiverLearning®: Alcoholic Liver Disease SIG: Alcoholic Hepatitis: New Therapeutic Strategies Beyond Prednisolone

Alcoholic Hepatitis is the most severe form of Alcoholic Liver Disease (ALD). Currently the most effective form of treatment is Prednisolone, to which many patients do not respond. In the last years, there has been great interest in the development of new targeted therapies for alcoholic hepatitis. In the U.S., there are 4 NIAAA-funded consortia to develop such therapies.

LiverLearning®: Career Development Workshop

If you are considering a career in hepatology, this is the course for you. The Career Development Workshop will educate medical students or residents who are considering a career in hepatology about training opportunities as well as arm current GI and/ or hepatology fellows with knowledge to help them succeed in academic hepatology. Attendees will learn about clinical and basic science research, funding mechanisms, mentorship and important career crossroads.

LiverLearning®: Hepatitis C SIG: HCV Treatment in Persons Who Inject Drugs

As HCV therapies now achieve high rates of SVR across a broad spectrum of individuals in patient care, there is a need to consider those HCV-infected persons who are not or may have difficulty accessing care or engaging in HCV therapy. Additionally, aspects related to prevention of reinfection are relevant in these difficult to reach populations. This program is targeting HCV SIG clinicians, public and global health experts as well as patient advocates with the goal of sharing expertise on how to improve the cascade of care in the “difficult to reach” populations.Mark W. Russo Mark W.

LiverLearning®: Hepatotoxicity SIG: Drug-Induced Liver Injury Due to Chemotherapeutic Agents

A look at both traditional and new chemotherapeutic agents associated with liver injury will help attendees gain a working knowledge of agents that can cause liver injury, how the injury presents, and how to make the diagnosis. This program also offers new insight on the challenges for chemotherapeutic drug development, approval and post-marketing surveillance in the U.S.Jay H. Hoofnagle Jay H.

Subscribe to